Group 1 - The core announcement is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective January 1, 2026, while the previous President, Wu Xiaobin, retains his position as President and COO [1][2] - Wang Lai has been with BeiGene since 2011 and has held various R&D leadership roles, most recently serving as the Global Head of R&D since April 2021 [2] - Wang Lai's annual salary will be $750,000 (approximately 5.28 million RMB), with the potential for a performance-based bonus and a one-time equity incentive of $10 million in restricted stock units [1][2] Group 2 - BeiGene reported a revenue of 10.077 billion RMB for Q3 2025, representing a year-on-year growth of 41.1%, and a net profit of 689 million RMB, marking a return to profitability [3] - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion RMB, with a year-on-year increase of 44.2%, and a net profit of 1.139 billion RMB [3] - The company's leading product, Zebrutinib, generated global sales of 7.423 billion RMB in Q3 2025, ranking first among similar BTK inhibitors, with U.S. sales contributing 5.266 billion RMB [3]

Core Viewpoint - The company announced the appointment of Dr. Wang Lai as President and Global Head of R&D, effective immediately, to oversee R&D, business development, and alliance management functions [1] Group 1: Appointment Details - Dr. Wang Lai has been with the company since 2011, holding various leadership roles in R&D, and has served as the Global Head of R&D since April 2021 [1] - Prior to joining the company, Dr. Wang worked as a Research Director at Joyant Pharmaceuticals in Dallas, Texas, from 2008 to 2011 [1] - Dr. Wang holds a Bachelor of Science degree from Fudan University (1996) and a Ph.D. from the University of Texas Health Science Center at San Antonio (2001) [1]

2025.12.19 本文字数：666，阅读时长大约1分钟 作者 |第一财经林志吟 事实上，在百济神州高管团队中，吴晓滨、汪来都属于代表性人物。汪来主管研发，他也是公司BTK抑制剂泽布替尼研发的主要领导者之一。作为百济神 州收入最高的自研产品，泽布替尼2024年以26亿美元的销售额，位居全球抗肿瘤药物销售排名第20位。泽布替尼的成功，既源于药物疗效上的突破，也源 于商业化上的成功。汪来带领的研发团队，与吴晓滨带领的商业化团队，配合默契。 如今，随着汪来履新百济神州总裁，公司也进入双总裁阶段。 微信编辑| 七三 第一财经持续追踪财经热点。若您掌握公司动态、行业趋势、金融事件等有价值的线索，欢迎提供。专用邮箱：bianjibu@yicai.com （注：我们会对线索进行核实。您的隐私将严格保密。） 12月18日晚间，百济神州（ONC.NS、06160.HK、688235.SH）发布的一则关于聘任公司高级管理人员的公告引发市场猜想。 公告显示：2025年12月17日，经百济神州有限公司（以下简称"公司"）董事会审议通过，公司董事会同意聘任公司全球研发负责人汪来博士担任公司总 裁，全球研发负责人。聘任生效后，汪来博士 ...

2025.12. 19 以26亿美元的销售额，位居全球抗肿瘤药物销售排名第20位。泽布替尼的成功，既源于药物疗效上 的突破，也源于商业化上的成功。汪来带领的研发团队，与吴晓滨带领的商业化团队，配合默契。 如今，随着汪来履新百济神州总裁，公司也进入双总裁阶段。 本文字数：666，阅读时长大约1分钟 作者 | 第一财经 林志吟 12月18日晚间，百济神州（ONC.NS、06160.HK、688235.SH）发布的一则关于聘任公司高级管 理人员的公告引发市场猜想。 公告显示：2025年12月17日，经百济神州有限公司（以下简称"公司"）董事会审议通过，公司董事 会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。聘任生效后，汪来博士担 任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等职能。 在此之前，百济神州的总裁只有一位，即吴晓滨，他也同时是百济神州首席运营官；汪来则是百济神 州高级副总裁以及全球研发负责人。 随着汪来担任公司总裁职位，吴晓滨的职位是否会有变动？ 百济神州内部人士回复第一财经记者称，吴晓滨博士的职务职责无变动，依然担任百济神州总裁兼首 席运营官，并全面 ...

Group 1 - The core management team of BeiGene has undergone a significant adjustment, with Dr. Wang Lai appointed as President while retaining his role as Global Head of R&D, overseeing key functions such as R&D, business development, and alliance management [1] - Dr. Wu Xiaobin, who previously held the position of President, remains in his role as President and Chief Operating Officer, making BeiGene the first pharmaceutical company to establish a "dual president" position [1] - In August, BeiGene also experienced a major personnel change with the appointment of Sean Shan, former Senior Vice President at Takeda Pharmaceuticals, as General Manager for Greater China, Central Asia, and South Asia, reporting to Dr. Wu Xiaobin [1] Group 2 - BeiGene has shown strong growth as a leading innovative drug company, achieving total revenue of 17.518 billion yuan in the first half of the year, representing a year-on-year increase of 46.0% [2] - The net profit attributable to the parent company reached 450 million yuan, marking a turnaround from losses in the same period last year [2] - The management team is expected to drive further business upgrades, and the company will continue to provide updates on any new developments [2]

此前数年，吴晓滨一直是百济神州的 核心人物 ，2025年6月 以前，其同时担任总裁、首席运营官兼中国区总经理。目前， 吴晓滨仍担任首席运营官和中国区总经理。 作者：张铃 封图：图虫创意 汪来自2021年4月起担任百济神州全球研发负责人。在此之前，他自 2011 年加入百济神州，担 任过多个研发领导职务，职责逐渐扩大。加入百济神州之前，汪来分别在复旦大学获得理学学士学 位，在德克萨斯大学圣安东尼奥健康科学中心获得博士学位，并于2008年至2011年在位于美国德 克萨斯州达拉斯的生物技术公司Joyant Pharmaceuticals担任研究主管。 据复旦大学校友总会2021年发布的一篇对汪来的专访，汪来从小是个"神童"，14岁就考入复旦， 成为少年大学生，24岁美国博士毕业。博士毕业后，汪来前往美国德州西南医学中心王晓东团队 做博士后。 王晓东是百济神州的创始人之一。2010年，王晓东与汪来讨论，想在中国创建一家生物制药公 司，王晓东非常看好以创新药为方向的中国医药企业的未来。他找到汪来，希望他回国，一起参与 创办百济神州。经过慎重思考，34岁时，汪来决定回国，而且是带着全家一起回国，后来，他成 为百济神州最重 ...

Group 1 - The company has entered a dual presidency phase with the appointment of Dr. Wang Lai as the new president, alongside the existing president, Dr. Wu Xiaobin [1][3] - Dr. Wang will oversee the company's research and development, business development, and alliance management functions [1] - Dr. Wu will continue in his role as president and COO, responsible for global commercialization, production, and supply chain operations [3] Group 2 - Dr. Wang is a key figure in the company, having led the development of the BTK inhibitor, Zebutinib, which is projected to generate $2.6 billion in sales in 2024, ranking 20th in global oncology drug sales [3] - The success of Zebutinib is attributed to both its therapeutic breakthroughs and effective commercialization strategies [3] - The collaboration between Dr. Wang's R&D team and Dr. Wu's commercialization team has been noted as highly effective [3]

Group 1 - The core point of the article is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective January 1, 2026, with a significant compensation package [1] - Wang Lai will receive an annual salary of $750,000 (approximately 5.28 million RMB) and is eligible for an annual target bonus equivalent to 75% of his base salary [1] - BeiGene will grant Wang Lai a one-time equity incentive of $10 million in the form of restricted stock units [1] Group 2 - Prior to his appointment, Wang Lai served as the Global Head of R&D at BeiGene since April 2021 and has held various leadership roles in R&D since joining the company in 2011 [2] - Wang Lai has an impressive academic background, having obtained a Bachelor's degree from Fudan University and a Ph.D. from the University of Texas Health Science Center [2] - He was a key leader in the development of the important drug, Zebrutinib, and was encouraged by BeiGene's co-founder, Wang Xiaodong, to return to China to help establish the company [2]

Core Viewpoint - BeiGene announced that Wu Xiaobin remains in his position as President and Chief Operating Officer, while Wang Lai has been appointed as the new President and Global Head of R&D, effective immediately [1] Group 1 - Wu Xiaobin's role in the company has not changed, continuing as President and COO [1] - The board of BeiGene approved the appointment of Wang Lai as President and Global Head of R&D [1] - Wang Lai will oversee the company's research, business development, and management of business alliance relationships [1]

Group 1: Eli Lilly - Eli Lilly has submitted a new oral weight loss drug, orforglipron, for FDA approval, indicating a competitive edge in the weight loss medication market [1] - Participants switching from Novo Nordisk's Wegovy to orforglipron maintained most of their weight loss, with an average rebound of only 0.9 kg [1] Group 2: Fosun Pharma - Fosun Pharma's subsidiary has signed a collaboration agreement with Clavis Bio, which could yield up to $363 million in payments [2] - Clavis Bio will have exclusive global rights (excluding mainland China, Hong Kong, and Macau) for development, production, and commercialization of the selected targets [2] - Fosun Pharma will also gain a minority stake in a new project company established by Clavis Bio for this collaboration [2] Group 3: Baidu - Baidu has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [3] - The issuance and listing are subject to shareholder approval and regulatory approvals, with specific details yet to be finalized [3] Group 4: BeiGene - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, reflecting the company's commitment to innovation in drug development [4] - Dr. Wang has been with BeiGene since 2011 and has progressively taken on more responsibilities in R&D leadership [4] Group 5: Junshi Biosciences - Junshi Biosciences announced that major shareholder Shanghai Tanying plans to reduce its stake by up to 2%, equating to approximately 2,053,380 shares [5] - The reduction is scheduled between January 13, 2026, and April 10, 2026, despite the shareholder's long-term confidence in the company's prospects [5]